hotspot -WSS

hotspot

author：comprehensive 2025-10-02 17:35:01 - browse：33

Peter Marks, Director of the Center for Biologics Evaluation and Research at the US Food and Drug Administration (FDA), testifies during a Senate Health, Education, Labor and Pensions Committee hearing to discuss the on-going federal response to Covid-19 on May 11, 2021 at the US Capitol in Washington, DC. — FDA's Peter Marks JIM LO SCALZO/POOL/AFP via Getty Images

WASHINGTON — The Food and Drug Administration needs dozens more reviewers if it wants its so-called Operation Warp Speed for rare disease therapies to take off, the agency’s biologics chief said Monday.

The administration launched the rare disease pilot program, dubbed START and modeled after the record race for a Covid-19 vaccine, this September. Peter Marks, head of the Center for Biologics Evaluation and Research, has spearheaded both initiatives.

“If we were really to expand this significantly, [it] would require us to get dozens of additional staff members,” Marks told listeners during a gene therapy discussion hosted by the Alliance for a Stronger FDA. “One could say ‘Oh my goodness, he’s asking for more headcount again.’ Well, if this really does reduce the time to development by 25 to 50% … it probably won’t take industry too long to do a net present value calculation to say ‘Oh, it’s worth making sure that they have their extra 20 or 30 or 40 reviewers.’”

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： In Memoriam: Notable people who died in 2023
Next article： A Q&A with Aletha Maybank, AMA’s chief health equity officer

WSS

ASCO: AstraZeneca says CAR

Change Healthcare cyberattack outage could last weeks

Shifting the focus from loneliness to social health

AstraZeneca loses challenge to Medicare drug price negotiation

Woman returns to dialysis after doctors remove transplanted pig kidney

Kristina Burow of ARCH Venture Partners shares her next big bets STAT

explore

hotspot

focus

Guidelines to prevent youth baseball injuries need more muscle

ALS groups 'won't be played again' by the FDA, drug sponsors

Continuity nursing helped my family in our darkest PICU moments

ASCO 2024: 'Reassuring' Corbus data on ADC bladder cancer drug

As demand for Covid shots wanes, Moderna seeks its next success

Abortion pill mifepristone to soon be dispensed at CVS, Walgreens

Sports medicine is finally prioritizing gender equality

Pfizer highlights cancer drugs it thinks could reignite investor interest

Sports medicine is finally prioritizing gender equality

ALS groups 'won't be played again' by the FDA, drug sponsors

explore

Abortion pill mifepristone to soon be dispensed at CVS, Walgreens

Let's speed up science by embracing open access publishing

For one rare type of lung cancer, Pfizer pill reduces progression by 81%

House looks to weaken Medicare negotiation

An inside look at PIPEs, biotech's buzzy new financing tool

Clinical trials giant ICON acquires HumanFirst

focus

entertainment

focus

focus